Skip to main content
Lyrea avatar

Not yet reviewed — this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

N-Methylbisfluoromodafinil

N-Methylbisfluoromodafinil molecule structureN-Methylbisfluoromodafinil molecule structure
Psychoactive Class
EugeroicStimulantNootropic
Chemical Class
Diphenylmethanethiol

N-Methylbisfluoromodafinil is an obscure nootropic substance of the benzhydryl class. It is the bis-fluoro-N-methyl analogue of modafinil, featuring fluorine substitutions on both of its benzene rings and a methyl group on the amide nitrogen. Despite its structural relationship to modafinil and adrafinil, it has no established research history, and neither pharmacological nor safety-profile similarities to these related compounds should be assumed.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~25 mg
Light25-100 mg
Moderate100-150 mg
Strong150-200 mg
Heavy200+ mg

Duration

Total5-8 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

The experience is that of a subtle, functional eugeroic state closely resembling modafinil, characterized by sustained wakefulness and improved task focus rather than overt recreational stimulation. Effects come on gradually and persist for an extended period, with little in the way of euphoria or sensory alteration. Anecdotal accounts describe it as somewhat more potent by weight than modafinil, with an otherwise comparable character.

Physical

Physical effects are limited to mild stimulation and prolonged wakefulness, often accompanied by reduced appetite. Taken late in the day, the extended duration can interfere with sleep.

Stimulation

Uncomfortable

Cognitive

The headspace is clear and unremarkable, with enhanced ability to sustain attention on tasks and a mild sense of increased mental drive. There is no notable emotional or perceptual component.

Enhancements

Motivation enhancement

Pharmacology

Pharmacodynamics

N-Methylbisfluoromodafinil has not been subject to pharmacological research beyond a single paper addressing its chemical properties. It is a benzhydryl compound structurally derived from flmodafinil (bisfluoromodafinil) through the addition of an N-methyl group on the amide nitrogen. Flmodafinil, the closest characterized structural relative, acts as a selective dopamine reuptake inhibitor. Whether N-methylbisfluoromodafinil shares this mechanism or a comparable binding profile has not been established.

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance
Many effects can become less responsive after sustained repeated use, leading users to need higher amounts for similar results.
Baseline Reset
1-2 weeks
Half Tolerance
3-7 days
Cross Tolerance

Modafinil analogs

Harm Potential

Addiction & Dependence

Psychological

Low

Considered mildly addictive with a low potential for abuse. The lack of euphoria or significant recreational effects appears to reduce psychological dependence liability in most users.

Physical

If dependence develops, cravings and withdrawal effects may occur upon sudden cessation, though the nature and severity of withdrawal has not been systematically studied.

History & Culture

N-Methylbisfluoromodafinil is an obscure nootropic substance of the benzhydryl class with no documented history of formal research. It is structurally related to the established wakefulness-promoting agents modafinil and adrafinil, being the N-methylated derivative of bisfluoromodafinil (also known…

Legality

Legality not written up yet

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed — this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes7 human edits · latest

Times are UTCNewest first

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the N-Methylbisfluoromodafinil article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.